TNF-α-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben

Research output: Review article

1 Citation (Scopus)


The introduction of TNF-α blocking therapy has produced a dramatic change in the treatment of therapy resistant patients with inflammatory bowel disease. Both infliximab and adalimumab are effective in middle severe and severe Crohn's disease. Besides, infliximab is potent in the remission and its sustaining in ulcerative colitis. However, among therapy resistant individuals, 20-30 percents of patients with Crohn's disease and 30-40 percents of patients with ulcerative colitis do not respond to these treatments. To date, no comparative study between the two drugs has been carried out and the clinical trials can not be directly compared to each others, still, on the basis of general considerations, there is no essential difference in the effectiveness between the two treatments.

Translated title of the contributionTNF-α blocking therapy in chronic inflammatory bowel disease
Original languageHungarian
Pages (from-to)1773-1779
Number of pages7
JournalOrvosi hetilap
Issue number38
Publication statusPublished - szept. 1 2009


  • Adalimumab
  • Crohn's disease
  • IBD
  • Infliximab
  • TNF-α
  • Ulcerative colitis

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'TNF-α-blokkoló kezelés krónikus, ismeretlen eredetu gyulladásos bélbetegségekben'. Together they form a unique fingerprint.

  • Cite this